NCT04418674

Brief Summary

This is a prospective comparative study which will be conducted in patients with proximal femur fracture undergoing operative interventions under subarachnoid block in sitting position. Ketamine group will receive 0.3mg/kg intravenously and Fentanyl group will receive 1.5mcg/kg before changing the position from supine to sitting for subarachnoid block. Analgesic effectiveness of the two drugs will be compared by Numeric Rating Scale for pain. Research hypothesis (Null hypothesis) There is no difference in analgesic effectiveness, patient satisfaction, spinal performance and occurrence of adverse effects between Intravenous ketamine and intravenous fentanyl in patients with proximal femur fracture. Alternate hypothesis Intravenous Ketamine in patients with proximal femur fracture improves the level of analgesia, patient satisfaction, spinal performance and occurrence of adverse effects when compared to intravenous fentanyl.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
52

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jun 2020

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 31, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 5, 2020

Completed
20 days until next milestone

Study Start

First participant enrolled

June 25, 2020

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2021

Completed
Last Updated

April 6, 2021

Status Verified

June 1, 2020

Enrollment Period

11 months

First QC Date

May 31, 2020

Last Update Submit

April 3, 2021

Conditions

Keywords

Spinal anesthesiaKetamineFentanyl

Outcome Measures

Primary Outcomes (1)

  • Numeric Rating Scale for Pain

    Level of analgesia for subarachnoid block in sitting position measured by Numeric Rating Rating Scale for pain. Scale ranges from 0 to 10, where 0 is no pain and 10 being maximum/ worst imaginable pain.

    1 to 20 minutes

Secondary Outcomes (6)

  • Likert Satisfaction score

    1 to 20 minutes

  • Anesthetist Satisfaction Score

    1 to 20 minutes

  • Number of attempts for successful spinal needle placement

    1 to 20 minutes (While performing subarachnoid block)

  • Adverse effects

    1 to 120 minutes (Intraoperatively)

  • Modified Wilson Sedation Scale

    1 to 120 minutes (Intraoperatively)

  • +1 more secondary outcomes

Study Arms (2)

Ketamine

EXPERIMENTAL

Patient will be given Ketamine 0.3mg/kg intravenously before sitting positioning for subarachnoid block.

Drug: Ketamine

Fentanyl

ACTIVE COMPARATOR

Patient will be given Fentanyl 1.5mcg/kg intravenously before sitting position for subarachnoid block.

Drug: Fentanyl

Interventions

in this group, patient will receive ketamine at 0.3mg/kg intravenously.

Ketamine

In this group, the patients will receive fentanyl at 1.5mcg/kg intavenously.

Fentanyl

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients undergoing Subarachnoid block for proximal fracture femur
  • Age: above 18 years
  • ASA PS I, II

You may not qualify if:

  • Refusal to participate in the study
  • Other painful co- morbidities
  • Allergy or any contraindication to study medication
  • Any contraindication to subarachnoid block
  • Analgesics 8 hours prior to performing sunarachnoid block
  • Pathologic fractures

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

B P Koirala Institute of Health and Sciences

Dharān, Sunsari, 56700, Nepal

RECRUITING

B P Koirala Institute of Health and sciences

Dharān, Sunsari, Nepal

RECRUITING

Related Publications (4)

  • Diakomi M, Papaioannou M, Mela A, Kouskouni E, Makris A. Preoperative fascia iliaca compartment block for positioning patients with hip fractures for central nervous blockade: a randomized trial. Reg Anesth Pain Med. 2014 Sep-Oct;39(5):394-8. doi: 10.1097/AAP.0000000000000133.

    PMID: 25068412BACKGROUND
  • Sia S, Pelusio F, Barbagli R, Rivituso C. Analgesia before performing a spinal block in the sitting position in patients with femoral shaft fracture: a comparison between femoral nerve block and intravenous fentanyl. Anesth Analg. 2004 Oct;99(4):1221-1224. doi: 10.1213/01.ANE.0000134812.00471.44.

    PMID: 15385380BACKGROUND
  • The safety, benefits and effectiveness of different intravenous subanesthetic doses of ketamine when combined with small dose of midazolam before combined spinal epidural technique for Orthopedic Lower Extremity Surgery Moataz Moataz Morad El-Tawil Anesthesia Department, Faculty of Medicine, Menoufya University Abstract

    BACKGROUND
  • Aral A Mohammed, MD*, Mayada M Ali, MD.Ketamine analgesia before spinal anesthesia for fractured femur. Sudan Med J 2015;April;51(1)

    BACKGROUND

MeSH Terms

Interventions

KetamineFentanyl

Intervention Hierarchy (Ancestors)

CyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Bishnu Pokharel, MS

    B P Koirala Institute of Health and Sciences

    STUDY CHAIR

Central Study Contacts

Jenny Bajracharya, MD

CONTACT

Krishna Pokharel, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
0.4ml from one 1 ml ampule of 50mg ketamine will be diluted with 9.6ml NS to make a concentration of 2mg Ketamine in each ml in a 10 ml syringe. One 2ml ampule of 100mcg Fentanyl will be diluted with 8 ml NS to make a concentration of 10mcg in each ml in a 10ml syringe Ketamine and Fentanyl will be administered as clear fluid from a 10ml syringe labelled as Study drug, therefore, both the patient and investigator will be blinded.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Ketamine Group: Ketamine 0.3mg/kg intavenously before changing the position from supine to sitting for subarachnoid block. Fentanyl group: Fentanyl 1.5mcg/kg intravenously before changing the position from supine to sitting position for subarachnoid block.
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Department of Anesthesia, Principal Investigator, Junior resident

Study Record Dates

First Submitted

May 31, 2020

First Posted

June 5, 2020

Study Start

June 25, 2020

Primary Completion

May 31, 2021

Study Completion

May 31, 2021

Last Updated

April 6, 2021

Record last verified: 2020-06

Data Sharing

IPD Sharing
Will not share

Locations